Beyond target lesions: Prognostic value of longitudinal AI-derived whole-body [1⁸F]FDG PET/CT metrics in metastatic melanoma
Christos Sachpekidis, Theodoros P. Vagenas, Marilena Müller, Dimitrios Strauss, Annette Kopp-Schneider, Leyun Pan, Jessica C. Hassel, George K. Matsopoulos, Antonia Dimitrakopoulou-Strauss · 2026
Read Beyond target lesions: Prognostic value of longitudinal AI-derived whole-body [1⁸F]FDG PET/CT metrics in metastatic melanoma by Christos Sachpekidis, Theodoros P. Vagenas, Marilena Müller, Dimitrios Strauss, Annette Kopp-Schneider, Leyun Pan, Jessica C. Hassel, George K. Matsopoulos, Antonia Dimitrakopoulou-Strauss (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13421226.txt.
Description
Christos Sachpekidis and colleagues tested AI-measured whole-body tumor burden in 2026 for predicting survival in metastatic melanoma on immunotherapy. Standard response rules judge a few target lesions, yet total tumor volume and glycolysis across the body may carry more prognostic weight.
Among 43 patients scanned at baseline, after two cycles, and after four cycles, baseline totals did not predict survival, while higher interim and late totals did, even alongside standard criteria. Oncologists gain evidence that AI whole-body PET measures at follow-up scans sharpen prognosis beyond target-lesion rules in everyday oncology.
Catalog record
| CREATOR | Christos Sachpekidis, Theodoros P. Vagenas, Marilena Müller, Dimitrios Strauss, Annette Kopp-Schneider, Leyun Pan, Jessica C. Hassel, George K. Matsopoulos, Antonia Dimitrakopoulou-Strauss |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 50 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |